Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:barrelLength |
high
|
| gptkbp:clinicalTrials |
Phase 1
|
| gptkbp:collaborations |
clinical partners
|
| gptkbp:contraindication |
immune-related adverse events
|
| gptkbp:currentStatus |
conducted
|
| gptkbp:developedBy |
gptkb:Xencor
|
| gptkbp:dosageForm |
every 2 weeks
|
| gptkbp:formulation |
liquid
|
| https://www.w3.org/2000/01/rdf-schema#label |
XmAb®20717
|
| gptkbp:isPortrayedBy |
2015
|
| gptkbp:mandates |
cancer
|
| gptkbp:patentAssignee |
gptkb:Xencor,_Inc.
|
| gptkbp:regulatoryCompliance |
investigational_new_drug_(IND)
|
| gptkbp:relatedTo |
gptkb:Nivolumab
immune system |
| gptkbp:researchFocus |
oncology
|
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
monitored
|
| gptkbp:status |
under investigation
|
| gptkbp:targets |
PD-1
patients with solid tumors |
| gptkbp:triggerType |
immune checkpoint inhibition
|
| gptkbp:type |
immunotherapy
|